

# Mammography Registry Practice Exam (Sample)

## Study Guide



**Everything you need from our exam experts!**

**Copyright © 2025 by Examzify - A Kaluba Technologies Inc. product.**

**ALL RIGHTS RESERVED.**

**No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.**

**Notice: Examzify makes every reasonable effort to obtain from reliable sources accurate, complete, and timely information about this product.**

**SAMPLE**

## **Questions**

SAMPLE

- 1. Is it possible to apply excessive compression to a breast during imaging?**
  - A. Yes**
  - B. No**
- 2. How does aging influence breast cancer risk?**
  - A. Age is the least significant risk factor**
  - B. Aging is a major risk factor for breast cancer**
  - C. Aging has no relation to breast cancer**
  - D. Only age-related hormonal changes affect risk**
- 3. A patient presents with a lumpectomy scar and informs the technologist that her breast is sensitive from radiation therapy. What should the technologist not do?**
  - A. Provide the results to the patient as quickly as possible.**
  - B. Inform the patient that additional images may be necessary.**
  - C. Gentle positioning and compression of the BCT breast.**
  - D. No concessions need to be made when imaging this patient.**
- 4. Which of the following modalities are amenable to performing a breast needle biopsy?**
  - A. MRI**
  - B. Ultrasonography**
  - C. Stereotactic breast biopsy**
  - D. All of the above**
- 5. What does the presence of microcalcifications on a mammogram suggest?**
  - A. Only benign conditions**
  - B. Infection**
  - C. Possibility of ductal carcinoma in situ (DCIS)**
  - D. Increased breast size**

- 6. When should women with a family history of breast cancer consider beginning screenings?**
- A. At age 30**
  - B. 10 years before the age of their diagnosed relative**
  - C. At age 50**
  - D. Only when symptoms appear**
- 7. What is the average radiation dose from a standard mammogram?**
- A. 0.1 mSv**
  - B. 0.4 mSv**
  - C. 1.0 mSv**
  - D. 2.5 mSv**
- 8. Which of the following reflects the differences in QC procedures across manufacturers?**
- A. Different QC tests names**
  - B. Variability in required test frequencies**
  - C. Different acceptance parameters**
  - D. All of the above**
- 9. What is the expected outcome of adjuvant therapy in breast cancer patients?**
- A. To cure cancer completely**
  - B. To prevent cancer recurrence**
  - C. To eliminate the need for surgery**
  - D. To reduce treatment duration**
- 10. Which portion of the breast is excluded during the performance of the CC projection?**
- A. Medial**
  - B. Anterior and central**
  - C. Inferior**
  - D. Posterior and superior tissue**

## **Answers**

SAMPLE

- 1. A**
- 2. B**
- 3. A**
- 4. D**
- 5. C**
- 6. B**
- 7. B**
- 8. D**
- 9. B**
- 10. D**

SAMPLE

## **Explanations**

SAMPLE



**1. Is it possible to apply excessive compression to a breast during imaging?**

**A. Yes**

**B. No**

Applying excessive compression to a breast during imaging is indeed possible and is an important consideration in mammography. Compression is a vital part of the mammography process, as it helps to reduce breast thickness, minimize motion, and improve image quality while also helping to limit radiation dose. However, if the compression is excessive, it can cause discomfort or pain to the patient and may also lead to potential artifacts in the imaging results. When too much pressure is applied, it can lead to distortion of breast tissue and affect the interpretation of the images, potentially masking lesions or mimicking pathology. This is why operators must be trained to apply an appropriate amount of compression, balancing the need for image clarity with patient comfort. Proper technique is essential to ensure that patients are not subjected to unnecessary pressure that could impact their experience and the diagnostic quality of the mammogram.

**2. How does aging influence breast cancer risk?**

**A. Age is the least significant risk factor**

**B. Aging is a major risk factor for breast cancer**

**C. Aging has no relation to breast cancer**

**D. Only age-related hormonal changes affect risk**

Aging is recognized as a significant risk factor for breast cancer due to several biological and hormonal changes that occur as women grow older. As women age, the cumulative exposure to estrogen, which is linked to breast tissue growth, increases. This prolonged exposure can lead to a higher likelihood of cellular mutations and the development of cancerous cells. Additionally, the risk of breast cancer increases significantly after the age of 50, particularly around menopause when hormonal changes further influence breast tissue composition. The studies indicate that the majority of breast cancer diagnoses occur in women over the age of 50, highlighting the correlation between aging and increased breast cancer risk. While hormonal changes are indeed part of the picture, they are not the only factor at play. Aging encompasses a variety of factors, including genetic predispositions and lifestyle choices, all of which contribute to the overall risk. Therefore, the characterization of aging as a major risk factor for breast cancer is well supported by research and clinical data, making it a crucial consideration in patient screening and management.

**3. A patient presents with a lumpectomy scar and informs the technologist that her breast is sensitive from radiation therapy. What should the technologist not do?**

- A. Provide the results to the patient as quickly as possible.**
- B. Inform the patient that additional images may be necessary.**
- C. Gentle positioning and compression of the BCT breast.**
- D. No concessions need to be made when imaging this patient.**

Providing the results to the patient as quickly as possible is not the appropriate action in this scenario. In a situation where the patient has a lumpectomy scar and is experiencing breast sensitivity due to radiation therapy, it's essential to prioritize patient comfort and safety. When dealing with sensitive breasts, particularly post-radiation or surgical intervention, the technologist should focus on minimizing discomfort and ensuring that the imaging process is as smooth as possible. While it's important to keep patients informed, delivering results immediately can lead to increased anxiety, especially in a sensitive situation like this, where the patient may already be feeling vulnerable due to her treatment journey. Instead, the technologist should ensure the patient feels comfortable and is adequately prepared for the imaging process, which can include explaining procedures, positioning gently, and possibly adjusting procedures based on the patient's comfort level.

**4. Which of the following modalities are amenable to performing a breast needle biopsy?**

- A. MRI**
- B. Ultrasonography**
- C. Stereotactic breast biopsy**
- D. All of the above**

Breast needle biopsy is a procedure used to obtain tissue samples from suspicious breast lesions for diagnostic purposes. All the modalities listed—MRI, ultrasonography, and stereotactic breast biopsy—can be utilized effectively for guiding needle biopsies, making the choice of “All of the above” the correct answer. MRI-guided needle biopsies are advantageous for lesions that are detectable by MRI but not palpable or visible on traditional imaging. They provide high-resolution images, allowing for precise targeting of the biopsy needle. Ultrasonography is widely used for guiding biopsies because it is readily available, offers real-time imaging, and allows for dynamic assessment of the lesion during the procedure. It is particularly effective for palpable masses or cysts. Stereotactic breast biopsy involves the use of mammography to precisely locate the lesion in a three-dimensional space, allowing for accurate needle placement. This method is especially beneficial for non-palpable lesions that can be identified through mammographic imaging. In summary, each modality plays a significant role in the biopsy process by providing specific advantages suited for different types of breast lesions, thus confirming that all these imaging techniques are amenable to performing breast needle biopsies.

**5. What does the presence of microcalcifications on a mammogram suggest?**

- A. Only benign conditions**
- B. Infection**
- C. Possibility of ductal carcinoma in situ (DCIS)**
- D. Increased breast size**

The presence of microcalcifications on a mammogram is significant as it can indicate the possibility of ductal carcinoma in situ (DCIS). Microcalcifications are tiny deposits of calcium that can appear in breast tissue. While some microcalcifications can be associated with benign conditions, their pattern and morphology are critical for interpretation. Clusters of microcalcifications, especially when they are irregular in shape or are heterogeneous, may suggest changes in the breast tissue that are indicative of malignancy, particularly DCIS. DCIS is a non-invasive form of breast cancer that originates in the milk ducts and has not yet spread beyond the ductal walls. Early detection through mammography can lead to better outcomes, which is why recognizing these signs is crucial for radiologists and healthcare providers. The other options do not accurately reflect the implications of microcalcifications seen on mammograms. For example, infection would not typically manifest as microcalcifications, and breast size increase is unrelated to the presence of microcalcifications. While benign conditions can cause microcalcifications, the particular characteristics associated with them more strongly suggest the potential for DCIS in certain contexts.

**6. When should women with a family history of breast cancer consider beginning screenings?**

- A. At age 30**
- B. 10 years before the age of their diagnosed relative**
- C. At age 50**
- D. Only when symptoms appear**

Women with a family history of breast cancer are advised to begin screenings 10 years before the age at which their diagnosed relative was diagnosed with the disease. This recommendation is based on the understanding that hereditary breast cancer can present at an earlier age than the general population. By starting screenings earlier, these women can benefit from early detection, which significantly increases the chances of successful treatment and survival. This approach is particularly important for those with known genetic predispositions, such as mutations in the BRCA1 or BRCA2 genes, which elevate the risk of developing breast cancer. Regular screenings, including mammograms and possibly additional imaging modalities, can help detect any abnormalities early on, thus facilitating timely intervention. In contrast, starting screenings at age 30 may not be appropriate unless there is a specific risk factor or family history indicating the need for earlier monitoring. Initiating screenings at age 50 is in line with general population guidelines but may miss the critical early detection window for those with a family history. Relying solely on symptoms to trigger screenings is not advisable, as many cases of breast cancer may be asymptomatic in their early stages. Therefore, proactive screening based on family history is essential for early detection and management of breast cancer risk.

**7. What is the average radiation dose from a standard mammogram?**

- A. 0.1 mSv
- B. 0.4 mSv**
- C. 1.0 mSv
- D. 2.5 mSv

The average radiation dose from a standard mammogram is approximately 0.4 mSv. This level of exposure is considered low and is comparable to the amount of natural background radiation a person would receive from the environment within a few days. Mammograms are designed to balance the need for clear images to detect potential breast cancers while minimizing radiation exposure to the patient. The figure of 0.4 mSv provides an effective guideline for understanding the safety and risks associated with this diagnostic imaging procedure. In the context of breast cancer screening, this dose is justified given the potential benefits of early detection, which outweigh the risks associated with radiation exposure. Understanding this average dose is essential for healthcare providers and patients when discussing mammography and its safety profile.

**8. Which of the following reflects the differences in QC procedures across manufacturers?**

- A. Different QC tests names
- B. Variability in required test frequencies
- C. Different acceptance parameters
- D. All of the above**

Quality control (QC) procedures in mammography can vary significantly between different manufacturers due to several factors. This variability encompasses differences in the tests that are required, how often they must be conducted, and the criteria that determine whether results are acceptable. Different QC tests names are indicative of the unique approaches each manufacturer may adopt in their engineering and technology. Each manufacturer may develop distinct tests that cater to the specific design and operational characteristics of their equipment, which means the terminology used can vary widely. Variability in required test frequencies is another important aspect of QC procedures. Manufacturers may establish different standards for how often QC tests should be performed based on their equipment's design, expected usage patterns, and regulatory requirements. This reflects the manufacturers' assessments of what is necessary to ensure optimal performance and safety of their mammography systems. Different acceptance parameters further illustrate the divergence in QC practices among manufacturers. Each manufacturer may set their own criteria for what constitutes acceptable performance based on extensive testing, reliability studies, and standards they prioritize. This can include varying thresholds for image quality, radiation dose, and other metrics critical for mammography. Considering these points, the correct answer encompasses all these aspects, confirming that QC procedures indeed differ across manufacturers in terms of test names, frequencies, and acceptance standards.

**9. What is the expected outcome of adjuvant therapy in breast cancer patients?**

- A. To cure cancer completely**
- B. To prevent cancer recurrence**
- C. To eliminate the need for surgery**
- D. To reduce treatment duration**

The expected outcome of adjuvant therapy in breast cancer patients is to prevent cancer recurrence. Adjuvant therapy refers to additional cancer treatment given after the primary treatment, which is usually surgery. The main goal of this therapy, which can include chemotherapy, radiation therapy, hormone therapy, or targeted therapy, is to eradicate any remaining cancer cells that could lead to a recurrence of the disease. By administering these treatments post-surgery, healthcare providers aim to reduce the risk of cancer returning in the same breast or in other parts of the body. This aspect of treatment is crucial as many breast cancers can return years after the initial diagnosis and treatment. While the ultimate hope in cancer treatment is often for a complete cure, adjuvant therapy specifically focuses on minimizing the likelihood of recurrence, thus improving long-term survival rates and patients' quality of life. It does not eliminate the need for surgery, nor does it necessarily reduce the duration of treatment; instead, it complements surgical efforts and extends the treatment timeline to ensure effectiveness against residual disease.

**10. Which portion of the breast is excluded during the performance of the CC projection?**

- A. Medial**
- B. Anterior and central**
- C. Inferior**
- D. Posterior and superior tissue**

The CC (Cranio-Caudal) projection is a standard mammographic view that captures the breast tissue from the top down, allowing radiologists to visualize and evaluate the glandular tissue effectively. In the CC projection, the focus is on visualizing the anterior and central portions of the breast, while the more superficial and posterior sections may be somewhat less visualized or excluded from the final imagery. This is primarily due to the positioning of the breast during the exam, which compresses the tissue to obtain a clearer view of the lesions and surrounding anatomy. The posterior and superior tissue might not be imaged adequately during the CC view, as the alignment and angle of the X-ray beam can cause these areas to be less represented. It is important for professionals interpreting these images to understand that this specific projection may not comprehensively capture all areas of breast tissue, particularly the posterior and superior aspects, which could be crucial for thorough evaluation and diagnosis. Therefore, the correct answer emphasizes the exclusion of these areas during the CC projection.